The revenue for Nimodipine is expected to reach an annual total of $52 mn by 2034 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Nimodipine Overview

Nimodipine (GTX-104) is under development for the treatment of aneurysmal subarachnoid hemorrhage (aSAH). The drug candidate is formulated as nanoparticle solution administered through intravenous route. Nimodipine acts by targeting the L-type calcium channel (Subunit Alpha 1F, Subunit Alpha 1D, Subunit Alpha 1C, Subunit Alpha 1S).

Acasti Pharma Overview

Acasti Pharma (Acasti), a subsidiary of Neptune Technologies & Bioressources Inc, is a biopharmaceutical company that conducts research, and development to formulate drug delivery capabilities to address rare and orphan diseases. Acasti is primarily focused on three underserved orphan diseases – Subarachnoid Hemorrhage (SAH), Ataxia Telangiectasia (A-T), and Postherpetic Neuralgia (PHN). The company develops phospholipid therapies for abnormalities in blood lipids and the treatment and prevention of various cardiometabolic disorders. Its product includes CaPre, a drug product candidate, used for the treatment of hypertriglyceridemia, which is a condition characterized by abnormally high levels of triglycerides in the bloodstream, and Onemia, a medical food that is used in the dietary management of diseases associated with omega-3 phospholipids deficiency related to cardiometabolic disorders. Acasti is headquartered in Laval, Quebec, Canada.
The operating loss of the company was US$52.2 million in FY2023, compared to an operating loss of US$15.6 million in FY2022. The net loss of the company was US$42.4 million in FY2023, compared to a net loss of US$9.8 million in FY2022.

For a complete picture of Nimodipine’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.